Sign In
Buy BGNE
$184.71
+0 (+0%)
At Close: Mar 28, 2025
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
06:00am, Wednesday, 04'th Dec 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL.
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
06:01am, Monday, 02'nd Dec 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today
BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US
09:00am, Sunday, 01'st Dec 2024
BeiGene's TEVIMBRA was just approved by the European Commission. The drug is poised to enter the EU and just reached the US market in October. BeiGene's revenue per share has grown significantly, wit
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, today annou
BeiGene to Present at Upcoming Investor Conferences
06:01am, Tuesday, 26'th Nov 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today
Labcorp CFO Glenn Eisenberg Announces Plans to Retire
07:00am, Tuesday, 19'th Nov 2024
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C. , Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory serv
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
06:00am, Tuesday, 19'th Nov 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company which intends to change its name to BeOne Medicines Ltd., today
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
06:00am, Thursday, 14'th Nov 2024
SAN MATEO, Calif. & BASEL, Switzerland--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
06:00am, Tuesday, 12'th Nov 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from t
BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion
01:35pm, Wednesday, 06'th Nov 2024
BeiGene, Ltd.'s TEVIMBRA shows promise with label expansion in Europe for 1st-line gastro/gastroesophageal junction cancer and 1st-line esophageal squamous cell carcinoma. BRUKINSA, a BTK inhibitor, g
BeiGene to Present at the Jefferies London Healthcare Conference
06:01am, Wednesday, 06'th Nov 2024
SAN MATEO, Calif. and BASEL, Switzerland--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
09:05am, Tuesday, 05'th Nov 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across a range of B-cel
BeiGene Mourns Death of Beloved Board Member Donald Glazer
06:00am, Monday, 28'th Oct 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is saddened to share the news that Donald Glazer recently pass
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for
BeiGene Highlights Waldenström's Macroglobulinemia Innovation at IWWM 2024
06:00am, Wednesday, 16'th Oct 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research from studies evaluating
